XML 69 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Asset Acquisitions and Collaboration Agreement - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 30, 2018
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2018
May 31, 2021
Jan. 01, 2021
 [1]
Dec. 31, 2020
 [2]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]              
Amortization expenses   $ 700,000 $ 1,300,000        
Amortization expenses, remainder period   1,200,000 1,200,000        
Amortization expenses, 2022   3,700,000 3,700,000        
Amortization expenses, 2023   3,700,000 3,700,000        
Amortization expenses, 2024   3,700,000 3,700,000        
Amortization expenses, 2025   3,700,000 3,700,000        
Amortization expenses, thereafter   30,000,000.0 30,000,000.0        
Capitalization of finite-lived intangible asset   46,204,000 46,204,000        
Other long-term liabilities   27,578,000 27,578,000     $ 8,425,000 $ 9,520,000 [1]
Other accrued liabilities   14,608,000 14,608,000       $ 13,349,000
Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc              
Business Acquisition Equity Interests Issued Or Issuable [Line Items]              
Capitalization of finite-lived intangible asset         $ 12,500,000    
Payment Following FDA Approval of Truseltiq              
Business Acquisition Equity Interests Issued Or Issuable [Line Items]              
Regulatory milestone payments         $ 20,000,000.0    
QED Therapeutics, Inc | Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc              
Business Acquisition Equity Interests Issued Or Issuable [Line Items]              
Regulatory milestone payments $ 12,500,000            
Regulatory milestone payments term 4 years            
Other long-term liabilities   11,000,000.0 11,000,000.0        
Other accrued liabilities   1,500,000 1,500,000        
QED Therapeutics, Inc | Maximum              
Business Acquisition Equity Interests Issued Or Issuable [Line Items]              
Regulatory milestone payments       $ 60,000,000.0      
Sales-based milestone payments       35,000,000.0      
Origin Biosciences, Inc.              
Business Acquisition Equity Interests Issued Or Issuable [Line Items]              
One-time final payment   $ 15,000,000.0 $ 15,000,000.0        
Origin Biosciences, Inc. | Maximum              
Business Acquisition Equity Interests Issued Or Issuable [Line Items]              
Sales-based milestone payments       17,000,000.0      
Assets acquisition required milestone payments       $ 18,800,000      
[1] Related deferred tax liability was recorded as part of “Other long-term liabilities.”
[2] The condensed consolidated balance sheet as of December 31, 2020 is derived from the audited consolidated financial statements as of that date.